Dual inhibition strategies, such as MEK inhibition in combination with BRAF, BET, and CDK4/6 inhibitors have been employed in neuroblastoma, but studies have reported limited anti-tumor activity or concerns of eventual escape and resistance [96,97,98,99]. The gene discussed is MAP2K7; the disease is neuroblastoma.